Zacks Research Has Negative Estimate for BMRN Q4 Earnings

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Research analysts at Zacks Research lowered their Q4 2025 earnings per share estimates for BioMarin Pharmaceutical in a research note issued to investors on Monday, November 17th. Zacks Research analyst Team now expects that the biotechnology company will post earnings per share of $0.70 for the quarter, down from their previous estimate of $0.75. Zacks Research has a “Hold” rating on the stock. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $3.15 per share.

A number of other equities analysts have also weighed in on BMRN. Morgan Stanley cut their price objective on shares of BioMarin Pharmaceutical from $104.00 to $98.00 and set an “overweight” rating for the company in a research report on Tuesday, October 28th. JPMorgan Chase & Co. lifted their target price on shares of BioMarin Pharmaceutical from $116.00 to $119.00 and gave the stock an “overweight” rating in a research note on Thursday, October 9th. Wall Street Zen lowered BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Saturday, November 1st. Wolfe Research restated an “outperform” rating on shares of BioMarin Pharmaceutical in a report on Tuesday, October 28th. Finally, Wedbush reiterated an “outperform” rating and issued a $94.00 target price on shares of BioMarin Pharmaceutical in a research note on Tuesday, October 28th. Sixteen analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $89.91.

BioMarin Pharmaceutical Price Performance

NASDAQ:BMRN opened at $54.16 on Wednesday. The firm has a market cap of $10.40 billion, a price-to-earnings ratio of 20.36, a price-to-earnings-growth ratio of 0.68 and a beta of 0.33. The company has a current ratio of 4.83, a quick ratio of 3.60 and a debt-to-equity ratio of 0.10. The company’s 50-day moving average is $53.74 and its two-hundred day moving average is $56.36. BioMarin Pharmaceutical has a 12-month low of $50.76 and a 12-month high of $73.51.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings data on Monday, October 27th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.20). The company had revenue of $776.13 million during the quarter, compared to analysts’ expectations of $782.42 million. BioMarin Pharmaceutical had a net margin of 16.82% and a return on equity of 9.53%. The firm’s revenue was up 4.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.91 earnings per share. BioMarin Pharmaceutical has set its FY 2025 guidance at 3.500-3.600 EPS.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Tokio Marine Asset Management Co. Ltd. raised its stake in shares of BioMarin Pharmaceutical by 0.9% in the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 22,523 shares of the biotechnology company’s stock worth $1,592,000 after buying an additional 197 shares in the last quarter. Securian Asset Management Inc. grew its holdings in BioMarin Pharmaceutical by 1.4% during the second quarter. Securian Asset Management Inc. now owns 14,604 shares of the biotechnology company’s stock worth $803,000 after acquiring an additional 197 shares during the period. Sittner & Nelson LLC raised its position in BioMarin Pharmaceutical by 6.9% in the second quarter. Sittner & Nelson LLC now owns 3,100 shares of the biotechnology company’s stock worth $170,000 after acquiring an additional 200 shares in the last quarter. Grandfield & Dodd LLC lifted its holdings in BioMarin Pharmaceutical by 1.2% in the 3rd quarter. Grandfield & Dodd LLC now owns 18,967 shares of the biotechnology company’s stock valued at $1,027,000 after acquiring an additional 217 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its holdings in BioMarin Pharmaceutical by 3.4% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 7,151 shares of the biotechnology company’s stock valued at $387,000 after acquiring an additional 235 shares during the last quarter. Institutional investors and hedge funds own 98.71% of the company’s stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.